Viekirax® (ombitasvir/ paritaprevir/ ritonavir) with or without Exviera® (dasabuvir): Not recommended in Child-Pugh B Patients

Kadar pengguna: 2 / 5

bintang aktifbintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif

Date: 3 March 2016



Postmarketing reports have been received of hepatic decompensation and hepatic failure in patients treated with Viekirax® with Exviera®, including cases involving liver transplantation or fatal outcomes. Most of the patients with severe outcomes had evidence of advanced or decompensated cirrhosis prior to starting the treatment. The product information will be updated with new safety information that the use of Viekirax® with or without Exviera® is not recommended in patients with moderate hepatic impairment (Child-Pugh B). Patients receiving Viekirax® and Exviera® should be counselled to watch for early symptoms of liver injury, and monitored for signs of hepatic problems. Please refer to the Direct Healthcare Professional Communication (DHPC) issued by AbbVie Sdn. Bhd. for further information.

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400



Image   Image   Image   Image  


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Khamis 13 Jun 2024, 10:32:42.
© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Menu Utama